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Abstract
Background: Breast cancer stem cells (BCSCs) are the source of breast tumors. Compared with other cancer cells,
cancer stem cells show high resistance to both chemotherapy and radiotherapy. Targeting of BCSCs is thus a
potentially promising and effective strategy for breast cancer treatment. Differentiation therapy represents one type
of cancer stem-cell-targeting therapy, aimed at attacking the stemness of cancer stem cells, thus reducing their
chemo- and radioresistance. In a previous study, we showed that down-regulation of CD44 sensitized BCSCs to the
anti-tumor agent doxorubicin. This study aimed to determine if CD44 knockdown caused BCSCs to differentiate
into breast cancer non-stem cells (non-BCSCs).
Methods: We isolated a breast cancer cell population (CD44
+CD24
- cells) from primary cultures of malignant breast
tumors. These cells were sorted into four sub-populations based on their expression of CD44 and CD24 surface
markers. CD44 knockdown in the BCSC population was achieved using small hairpin RNA lentivirus particles. The
differentiated status of CD44 knock-down BCSCs was evaluated on the basis of changes in CD44
+CD24
- phenotype,
tumorigenesis in NOD/SCID mice, and gene expression in relation to renewal status, metastasis, and cell cycle in
comparison with BCSCs and non-BCSCs.
Results: Knockdown of CD44 caused BCSCs to differentiate into non-BCSCs with lower tumorigenic potential, and
altered the cell cycle and expression profiles of some stem cell-related genes, making them more similar to those
seen in non-BCSCs.
Conclusions: Knockdown of CD44 is an effective strategy for attacking the stemness of BCSCs, resulting in a loss
of stemness and an increase in susceptibility to chemotherapy or radiation. The results of this study highlight a
potential new strategy for breast cancer treatment through the targeting of BCSCs.
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Background
The existence of breast cancer stem cells (BCSCs) in
malignant breast tumors has been demonstrated in
many previous studies [1-4]. These stem cells exhibit a
range of phenotypes, including CD44
+CD24
-,C D 4 4
+CD24
-/dim, CD44
+CD24
-/dimESA
+ and CD44
+CD24
-Lin
-
[1-4]. These cells possess specific characteristics, such as
anti-tumor-drug and radiation resistance [5]. Because
they can escape the effects of chemotherapy or radiation
therapy, relapse remains a possibility. The resistance of
t h e s ec e l l sm a yb em e d i a t e db ys i g n a l i n gt h r o u g ht h e
Wnt pathway [6]. They also express high levels of anti-
apoptotic proteins, such as survivin and Bcl [7], and evi-
dence suggests that alterations in DNA repair and cell
cycle kinetics may be involved in their resistance to
radiation and chemotherapy [8]. In addition, BCSCs
have been shown to be resistant to hormone therapy
[9-11]. The discovery of this cancer stem cell population
in breast tumors has thus opened up several potential
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terms of BCSC-targeting therapy.
The resistance of BCSCs to radiation and chemother-
apy means that there is a need to develop agents able to
attack this cell population. Because of their stemness,
targeting therapies have usually been designed to regu-
late the self-renewal characteristics, as well as the differ-
entiation of stem cells. Several strategies designed to
target BCSCs are currently available, and can be divided
into two main groups: those directly targeting BCSCs
and those that indirectly targeting BCSCs through the
cell microenvironment.
A number of developmental pathways responsible
for regulating stemness have been elucidated during
the past decade, including Wnt, Notch, and Hedge-
hog, and several studies have demonstrated that dis-
rupted regulation of these pathways can lead to the
development of breast cancer in mice [12-15] and
humans [16-18]. HER2 signaling represents one of
most significant advances in breast cancer research.
Trials of agents targeting HER2, such as trastuzumab
and lapatinib, have shown improved overall survival of
patients with advanced disease [19] as well as reduced
tumor recurrence [20]. Another study found that
HER2-targeting agents reduced the BCSC population
[19].
However, despite the remarkable clinical efficacy of
HER2-targeting agents, a third of HER2-positive tumors
do not respond to these agents as well as expected on
the basis of their reduced resistance, and almost 50% of
patients who respond to HER2-targeted agents relapse
within a year [21]. The reason for this phenomenon is
unclear. Moreover, nearly 50% of patients are negative
for HER2 [22]. Thus the search for new therapeutic
strategies continues worldwide.
The adhesion molecule CD44 is a cell surface trans-
membrane glycoprotein involved in lymphocyte activa-
tion, recirculation and homing, adhesion of extracellular
matrix, angiogenesis, and cell proliferation, differentia-
tion, and migration [23]. These properties are associated
with the pathologic activities of cancer cells. Previous
research demonstrated that knockdown of CD44 in
BCSCs sensitized them to the anti-tumor drug doxoru-
bicin [24], suggesting that CD44 knockdown affected
the stemness or differentiation of these cells.
The current study therefore aimed to investigate the
effects of CD44 knockdown on the stemness and differ-
entiation of BCSCs in severe combined immunodeficient
(SCID) mice in terms of gene expression, cell cycle, and
tumorigenesis, in comparison with breast cancer non-
stem cells (non-BCSCs). The results will facilitate the
development of BCSC-targeting differentiating gene
therapy for breast cancer treatment.
Materials and methods
Primary culture of breast cancer cells from malignant
breast tumors
Primary culture of breast cancer cells from malignant
breast tumors was carried outa sp r e v i o u s l yd e s c r i b e d
[4,24]. Briefly, tumor biopsies were obtained from con-
senting hospital patients then transferred to our labora-
tory. Biopsy samples were washed three to four times
with phosphate-buffered saline (PBS) supplemented with
1 × antibiotics and an antimycotic (Sigma-Aldrich, St
Louis, MO), and homogenized into small fragments
(approximately 1-2 mm
3) using scissors. Homogenized
samples were seeded in 35-mm culture dishes (Nunc,
Roskilde, Denmark) in M171 medium (Invitrogen, Carls-
bad, CA) containing mammary epithelial growth supple-
ment (Invitrogen, Carlsbad, CA), and incubated at 37°C
in 5% CO2. The medium was refreshed every third day,
and the cells were sub-cultured continuously until most
cells resembled epithelial-like cells. Ten patients were
included in this study, and cancer cells were isolated
from all 10 tumors by primary culture.
Isolation of four cancer cell populations based on CD44
and CD24 expression
All primary cultures were analyzed for the presence of
BCSCs by flow cytometry. The samples with the highest
percentage of BCSCs were used to isolate four cancer
cell populations, based on their expression of CD44 and
CD24. CD44
+CD24
- cell populations were classed as
BCSCs, while CD44
+CD24
+,C D 4 4
-CD24
+ and CD44
-
CD24
- cell populations were classed as non-BCSCs or
differentiated cells. In subsequent experiments, the term
“non-BCSCs” or “differentiated cells” refers to a mixture
of the CD44+CD24
+,C D 4 4
-CD24
+ and CD44
-CD24
-
cell populations. These four cancer cell populations
were isolated based on their cell surface expression of
CD44 and CD24 using a magnetic-activated cell sorting
(MACS) system with anti-CD44 and anti-CD24-biotin
combined anti-biotin microbeads (Miltenyi Biotec Inc.,
CA). Positive selection was performed using MS col-
umns, and negative selection using LD columns (Milte-
nyi Biotec Inc., CA). Cultured cells were detached by
trypsin/EDTA 0.25% (Sigma- A l d r i c h ,S tL o u i s ,M O ) .
CD44
+CD24
+ cells were isolated in two steps: cells were
initially stained with CD44 microbeads and CD44
+ cells
were collected; the CD44
+ cells were then stained with
anti-CD24-biotin, followed by anti-biotin microbeads to
isolate CD44
+CD24
+ cells. CD44
+CD24
-,C D 4 4
-CD24
+
and CD44
-CD24
- cells were similarly isolated by com-
bining positive collections or depletions based on CD44
and CD24 expression, using the same techniques. The
phenotypes of all isolated cells were confirmed by flow
cytometry using a BD FACSCalibur machine (BD
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CD44-phycoerythrin (PE) and anti-CD24-fluorescein
isothiocyanate (FITC) monoclonal antibodies (BD Bios-
ciences, Franklin Lakes, New Jersey). Their purities were
confirmed by flow cytometry, and samples with > 90%
purity were used for further experiments.
Knockdown of CD44
+CD24
- cells with small hairpin RNA
using lentivirus particles
CD44 small hairpin RNA (shRNA) lentivirus particles
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) were
stably transfected, according to the manufacturer’s
instructions. Briefly, CD44
+CD24
- cells were plated on
day 1 into 12-well plates with complete medium
(DMEM/F12 supplemented with 10% fetal bovine serum
and 1 × antibiotic-mycotic) and incubated overnight.
The medium was replaced on day 2 with fresh complete
medium supplemented with 5 μg/ml polybrene (Sigma-
Aldrich, St Louis, MO) for 6 h, after which 20 μlM E M
with 25 mM HEPES containing 10
5 infectious units of
virus were directly added into the culture. The plate was
shaken to mix the virus particles and incubated over-
night at 37°C in 5% CO2. The medium was changed on
day 3 to fresh complete medium without polybrene.
Successfully transduced cells were selected by culturing
in complete medium supplemented with 10 μg/ml puro-
mycin dihydrochloride (Sigma-Aldrich, St Louis, MO)
for 12 h, followed by 5 μg/ml puromycin dihydrochlor-
ide for 1 week. CD44 knockdown BCSCs were con-
firmed by determination of CD44 expression by flow
cytometry and immunocytochemistry. Samples with >
90% purity were used for further experiments for evalu-
ating tumorigenesis in SCID mice and investigating gene
expression and cell cycle.
Flow cytometry
Cells were washed twice in PBS supplemented with 1%
bovine serum albumin (Sigma-Aldrich, St Louis, MO).
The cell surface Fc receptor was blocked using IgG
(Santa Cruz Biotechnology, Inc., Santa Cruz, CA) on ice
for 15 min. Cells were stained for 30 min at 4°C with
anti-CD44-PE and anti-CD24 FITC monoclonal antibo-
dies (BD Biosciences, Franklin Lakes, New Jersey). After
washing, cells were analyzed using a FACSCalibur flow
cytometer (BD Biosciences, Franklin Lakes, New Jersey)
using CellQuest Pro software at 10,000 events.
Gene expression analysis
Ten random colonies formed after plating CD44 knock-
down BCSCs at low density were used for the analysis of
gene expression. To evaluate the differentiated status of
BCSCs, expression of 15 genes related to the properties
of cancer stem cells and cancer/normal cells, as well as
some genes related to signaling pathways over-expressed
in cancer stem cells, were analyzed in comparison with
BCSCs and non-BCSCs. Glyceraldehyde 3-phosphate
dehydrogenase (GAPDH; [Genebank:NM_002046]) was
used as an internal control for all experiments. All pri-
mers used in this study were designed using Primer Blast
software (NCBI). Primer pairs were chosen to give poly-
merase chain reaction (PCR) products of 100-350 bp.
The universal primer for each forward and reverse pri-
mer was then added. The universal primer sequence was
suggested by the manufacturer, using the GenomeLab
GeXP genetic analysis system (Beckman-Coulter, Brea,
California). All primer sequences are listed in Table 1.
All primers were checked for specificity and working sta-
tus by in silico PCR and in vitro reverse-transcription
PCR using a universal RNA template (Clontech, CA,
USA). Only primer pairs that gave the intended PCR pro-
ducts were used in subsequent experiments. Two multi-
plex PCR reactions were used to evaluate the change in
stemness: one multiplex with 17 genes included Bcl-2
[Genebank:NM_000633], Fos [Genebank: NM_005252],
ICAM1 [Genebank:NM_000201], CCND1 [Genebank:
NM_053056], MMP7 [Genebank:NM_002423], Myc
[Genebank:NM_002467], PRKCE [Genebank:
NM_005400], TP53 [Genebank:NM_000546], VCAM1
[Genebank:NM_001078], IL4R [Genebank:NM_000418],
PTCH1 [Genebank:NM_000264], HSPB1 [Genebank:
NM_001540], PTGS2 [Genebank: NM_000963], HSF1
[Genebank:NM_005526], LEF1 [Genebank:NM_016269],
TCF7 [Genebank:NM_003202], and FASN [Genebank:
NM_004104] and the other with five genes included
Muc-1 [Genebank:NM_002456], cyclin E2 [Genebank:
NM_004702], EGFR [Genebank:NM_005228], Myc [Gen-
ebank:NM_002467], and cyclin D1 [Genebank:
BC001501].
RNA was isolated from all cell samples using an RNA
isolation kit (Fermentas, Glen Burnie, Maryland, USA).
Gene expression levels of 15 genes involved in drug
resistance, cell cycle and signaling pathways were
assayed using the capillary GenomeLab GeXP genetic
analysis system (Beckman-Coulter, Brea, California). A
multiplex panel was designed to assess the genes. In
addition to the genes of interest, each panel contained
an internal control gene (kanamycin resistance, KanR)
and a normalization gene (GAPDH). cDNA was synthe-
sized from 500 ng total RNA using the GenomeLab
GeXP Start Kit (Beckman-Coulter, Brea, California).
PCR and multiplex detection were performed according
to the manufacturer’s instructions. GeXP data were ana-
lyzed after normalization of all genes of interest against
the geometric mean of the normalization gene.
Cell cycle assay
Cell cycle analysis was carried out according to the fol-
lowing protocols. Cells from each group were washed
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Gene Sequence GeXP PCR product
(bp)
Multiplex 1: 17 genes (+ GAPDH and KanR)
Bcl-2 (B-cell lymphoma 2) F:AGGTGACACTATAGAATATGGAACTGTACGGCCCCAGCA 140
[Genebank:NM_000633] R:GTACGACTCACTATAGGGAAGGGTGATGCAAGCTCCCACCA
Fos (FBJ murine osteosarcoma viral oncogene homolog) F:AGGTGACACTATAGAATAGTTATAAAAGCAGTGGCTGCGGC 153
[Genebank: NM_005252] R:GTACGACTCACTATAGGGAAGCACGGTCACTGCTCGTTCG
ICAM1 (intercellular adhesion molecule 1) F:AGGTGACACTATAGAATAGTGCTATTCAAACTGCCCTGA 169
[Genebank:NM_000201] R:GTACGACTCACTATAGGGAGCGTAGGGTAAGGTTCTTGC
CCND1 (cyclin D1) F:AGGTGACACTATAGAATAGCATGTTCGTGGCCTCTAAG 177
[Genebank: NM_053056] R:GTACGACTCACTATAGGGACAGGTTCCACTTGAGCTTGTT
MMP7 (matrix metalloproteinase-7) F:AGGTGACACTATAGAATATTGGCTTTGCGCGAGGAGCT 181
[Genebank:NM_002423] R:GTACGACTCACTATAGGGACTGCTACCATCCGTCCAGCGT
Myc (V-myc myelocytomatosis viral oncogene homolog
(avian))
F:AGGTGACACTATAGAATACTCTCCTTGCAGCTGCTTAGA 187
[Genebank:NM_002467] R:GTACGACTCACTATAGGGACCTCGTCGCAGTAGAAATACG
PRKCE (Protein kinase C epsilon type) F:AGGTGACACTATAGAATAAAGGTCCCTACCTTCTGCGA 197
[Genebank:NM_005400] R:GTACGACTCACTATAGGGACCAGTACTTTGGCGATTCCT
TP53 (Cellular Tumor Antigen p53) F:AGGTGACACTATAGAATATTCCCTGGATTGGCAGCCAGACTG 201.5
[Genebank:NM_000546] R:GTACGACTCACTATAGGGATCCATTGCTTGGGACGGCAAGG
VCAM1 (vascular cell adhesion molecule 1) F:AGGTGACACTATAGAATAAGGTGACGAATGAGGGGACCACATC 215.4
[Genebank:NM_001078] R:GTACGACTCACTATAGGGAAGCCTCCAGAGGGCCACTCAAA
IL4R (IL-4 receptor) F:AGGTGACACTATAGAATAAAGTGGCACAACTCCTACAGG 231
[Genebank:NM_000418] R:GTACGACTCACTATAGGGACCCTGAGCATCCTGGATTATT
PTCH1 (Protein patched homolog 1) F:AGGTGACACTATAGAATAGCCTTCGCTCTGGAGCAGATTT 240
[Genebank:NM_000264] R:GTACGACTCACTATAGGGAGTTGGTCTCGAGGTTCGCTGCTT
HSPB1(heat shock 27 kDa protein 1) F:AGGTGACACTATAGAATAGCACACTGACCGTGGAGGCC 241
[Genebank: NM_001540] R:GTACGACTCACTATAGGGAGAACACACAGGTGGCGGGGG
PTGS2 (prostaglandin-endoperoxide synthase 2) F:AGGTGACACTATAGAATACAGCTCCACAGCCAGACGCC 249
[Genebank: NM_000963] R:GTACGACTCACTATAGGGATCCTGTCCGGGTACAATCGCACT
HSF1 (Heat shock factor protein 1) F:AGGTGACACTATAGAATAGCCTTCCTGACCAAGCTGTGGACC 271
[Genebank:NM_005526] R:GTACGACTCACTATAGGGATCTCTCTGGCTTGACCAGGCCG
GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) F:AGGTGACACTATAGAATAAAGGTGAAGGTCGGAGTCAA 277.2
[Genebank:NM_002046] R:GTACGACTCACTATAGGGAGATCTCGCTCCTGGAAGATG
LEF1 (Lymphoid enhancer-binding factor-1) F:AGGTGACACTATAGAATAGGTGCAGCCATCCCATGCGGT 290.2
[Genebank:NM_016269] R:GTACGACTCACTATAGGGAAGGGTTGCCTGAATCCACCCGTG
TCF7 (Transcription factor 7) F:AGGTGACACTATAGAATAGGCGAGGAGCAGGACGACAAGAG 305
[Genebank:NM_003202] R:GTACGACTCACTATAGGGATTTGTACATGCCGCTGGTGCAC
FASN (Fatty acid synthase) F:AGGTGACACTATAGAATAGAGTCGGAGAACTTGCAGGAGT 307
[Genebank:NM_004104] R:GTACGACTCACTATAGGGAGTGTGTTCCTCGGAGTGAATCT
KanR (Kanamycin resistance) F:
AGGTGACACTATAGAATAATCATCAGCATTGCATTCGATTCCTGTTTG
325.4
R:GTACGACTCACTATAGGGAATTCCGACTCGTCCAACATC
Multiplex 1: 5 genes (+ GAPDH and KanR)
Muc-1 (Mucin 1, transmembrane, transcript variant 1) F:AGGTGACACTATAGAATAGACGTCAGCGTGAGTGATGT 177.7
[Genebank:NM_002456] R:GTACGACTCACTATAGGGAGACAGCCAAGGCAATGAGAT
Cyclin E2 (Cyclin E2 (CCNE2), transcript variant 3) F:AGGTGACACTATAGAATAGAGCCCGAAGAGCACTGAAAAACC 194.6
[Genebank:NM_004702] R:GTACGACTCACTATAGGGAGAGGAATTGGCTAGGGCAATCAA
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h at 4°C. Cells were then washed twice in PBS and
stained with 1 ml of PI (20 μg/ml). A 50-μlv o l u m eo f
RNase A (10 μg/ml) was added to the samples and incu-
bated for 3 h at 4°C. Stained cells were analyzed by flow
cytometry using CellQuest Pro software (BD Bios-
ciences, Franklin Lakes, New Jersey).
Tumorigenesis assay
Non-obese diabetic (NOD)/SCID mice (5-6 weeks old)
(NOD.CB17-Prkdcscid/J) (Charles River Laboratories)
were used in this research. Four experiments were per-
formed to evaluate the effects of CD44 knockdown on
the tumorigenic potential of BCSCs. In the first experi-
ment, BCSCs were injected into 12 mice with three mice/
dose at 10
6,1 0
5,1 0
4 and 10
3 cells/mouse. Similarly,
CD44 knockdown BCSCs and non-BCSCs were injected
at the same doses in the second and third experiments.
The fourth experiment comprised negative control mice
injected with PBS. The first and second, and third and
fourth experiments, respectively, were performed using
the right and left sides of the same mice. All mice were
housed in clean cages and maintained according to insti-
tutional guidelines on animal welfare. Mice were followed
up for 2 months to detect tumors.
Statistical analysis
All experiments were performed in triplicate. Differ-
ences between mean values were assessed by t-tests and
analysis of variance. A P value of ≤ 0.05 was considered
to be significant. Data were analyzed using Statgraphics
software (v 7.0; Statgraphics Graphics System, Warren-
ton, VA).
Results
Isolation and culture of BCSCs and non-BCSCs
Primary cultures were derived from 10 breast tumor
samples, including eight well-developed tumors with
many cells expanding from the tissues and two samples
that were infected with micro-organisms. The primary
cultures were sub-cultured to produce a large number
of cells, which were then evaluated for the presence of
BCSCs. BCSCs comprised 4.32 ± 1.78% of all the sam-
ples (range 2.51-7.09%) (Figure 1A, B). The sample with
the highest BCSC population was used to isolate four
populations based on the expression of CD44 and CD24
markers (CD44
+CD24
-, CD44
+CD24
+, CD44
-CD24
+, and
CD44
-CD24
- cells) by magnetic cell sorting. The purities
of the isolated cell populations assessed by flow cytome-
try ranged from 95.14-99.99% (Figure 1C-F). The four
cultured cell populations had homogeneous shapes (Fig-
ure 2) and were cultured and subcultured to produce
sufficient cells for further experiments.
Expression of CD44 in CD44 knockdown BCSCs
Following shRNA lentivirus transfection and selection
with puromycin for 1 week, CD44 knockdown BCSCs
showed decreased CD44 expression compared with
BCSCs before knockdown, as demonstrated by immuno-
cytochemistry and flow cytometry (Figure 3). Thus
CD44 shRNA lentivirus combined with puromycin
selection efficiently silenced CD44 mRNA expression in
treated cells. Protein quantification by flow cytometry
demonstrated that the percentage of CD44-positive cells
in BCSCs before and after CD44 knockdown was
reduced from 96.32% ± 3.33% to 0.12% ± 0.03% (n = 3)
(Figure 3D, H). This level of suppression was greater
than that achieved in a previous study using transfection
of small interfering RNA (siRNA) [24].
Gene expression in CD44 knockdown BCSCs compared
with BCSCs and non-BCSCs
The expression of important genes related to stemness,
anti-tumor drug resistance, and metastasis in BCSCs
was altered in CD44 knockdown BCSCs, as shown in
Figures 4 and 5. Muc-1, MMP9,a n dMyc expression
Table 1 Primer sequences used in this research. (Continued)
EGFR (EGF receptor, transcript variant 1) F:AGGTGACACTATAGAATAGAAAGGCAGCCACCAAATTA 208.4
[Genebank:NM_005228] R:GTACGACTCACTATAGGGAACTATCCTCCGTGGTCATGC
Myc (V-myc myelocytomatosis viral oncogene homolog
(avian))
F:AGGTGACACTATAGAATAGAGCAACGTCTCCACACATCAGCAC 217
[Genebank:NM_002467] R:GTACGACTCACTATAGGGAGAGTTTTGTGTGTTCGCCTCTTGAC
Cyclin D1 (G1/S-specific cyclin-D1) F:AGGTGACACTATAGAATACGTGGCCTCTAAGATGAAGG 252.5
[Genebank:BC001501] R:GTACGACTCACTATAGGGATGCGGATGATCTGTTTGTTC
GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) F:AGGTGACACTATAGAATAAAGGTGAAGGTCGGAGTCAA 277.2
[Genebank:NM_002046] R:GTACGACTCACTATAGGGAGATCTCGCTCCTGGAAGATG
KanR (Kanamycin resistance) F:
AGGTGACACTATAGAATAATCATCAGCATTGCATTCGATTCCTGTTTG
325.4
R:GTACGACTCACTATAGGGAATTCCGACTCGTCCAACATC
F: Forward; R: Reverse.
Pham et al. Journal of Translational Medicine 2011, 9:209
http://www.translational-medicine.com/content/9/1/209
Page 5 of 13levels were strongly reduced by CD44 knockdown,
bringing them in line with levels in non-BCSCs. Levels
of several other genes such as EGFR and cyclin D1 also
fell. High Bcl-2 expression in BCSCs is particularly asso-
ciated with chemoresistance, and its expression also
decreased to the level in non-BCSCs after knockdown of
CD44. The expression of genes related to stemness,
such as LEF1, also decreased. LEF1, TCF7,a n dMyc are
members of the Wnt signaling pathway; Bcl-2, MMP7,
and Myc are members of the PI3K/AKT signaling
Figure 1 Expression of CD44 and CD24 in four different cell populations analyzed by flow cytometry. (A) Unstained cells. The breast
cancer cell population (B) was sorted into four populations: CD44
+CD24
+ (C), CD44
-CD24
+ (D) and CD44
-CD24
- (E), CD44
+CD24
- (BCSCs) (F). All
sorted cell populations exhibited high degrees of purity.
Figure 2 Primary cells, breast cancer cells and four sub-populations of CD44
+CD24
+, CD44
+CD24
-, CD44
-CD24
- and CD44
-CD24
+ cells.
Cells expanding from the tissue (A) showed at least two different shapes (epithelial and stromal) and became homogeneous after sub-culturing
(B). These cells were sorted into four sub-populations of CD44
-CD24
+ (C), CD44
-CD24
- (D), CD44
+CD24
- (E) and CD44
+CD24
+ cells (F).
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Stress pathway; and PTCH1, PKRCE, PTGS2,a n dIL4R
are members of the Hedgehog signaling pathway.
Expression of all these genes was reduced to levels simi-
lar to those seen in non-BCSCs.
Cell cycle in CD44 knockdown BCSCs compared with
BCSCs and non-BCSCs
The cell cycle was affected by knock-down of CD44, as
shown in Figure 6. The percentage of cells in G2/M
phase was significantly higher in BCSCs compared with
Figure 3 CD44 expression before (A, B, C and D) and after CD44 knockdown by shRNA (E, F, G and H) combined with selection using
puromycin dihydrochloride for 1 week. Cells were evaluated by immunocytochemistry after staining with anti-CD44 and fluorescein-
isothiocyanate (FITC)-conjugated secondary antibody and were observed under a monochromatic fluorescence microscope (Carl Zeiss,
Oberkochen, Germany) with white light, Hoechst 33342 and a FITC filter (A and E, B and F, C and G, respectively) and by flow cytometry after
staining with anti-CD44-FITC (D and H).
Figure 4 Similar gene expression patterns in CD44 knockdown BCSCs (B, E) and non-BCSCs (C, F) compared with BCSCs (A, D), in
genes related to cell viability, proliferation, metastasis and anti-tumor drug resistance, analyzed using a genetic analysis system
(GeXP, Beckman-Coulter, Brea, California). Knocked down: CD44 knockdown BCSCs.
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Page 7 of 13non-BCSCs (28.60 ± 0.60% vs. 23.41% ± 0.50%, P < 0.05)
while the number of cells in S phase was lower (13.93 ±
0.69% vs 20.08 ± 0.31%, P < 0.05). In contrast, the num-
bers of cells in G1/G0 phase were similar in BCSCs and
non-BCSCs (57.47 ± 0.23% vs 56.51 ± 0.55%, P > 0.05).
G2/M phase and S phase in CD44 knockdown BCSCs
approached those in non-BCSCs. G2/M phase in CD44
knockdown BCSCs decreased and was similar to non-
BCSCs (24.23 ± 0.34% vs 23.41 ± 0.50%, respectively)
while S phase increased from 13.93 ± 0.69% in BCSCs
to 16.98 ± 0.95% in CD44 knockdown BCSCs, compared
with 20.08 ± 0.31% in non-BCSCs (Figure 6). The per-
centages of cells in G1/G0 phase in BCSCs, non-BCSCs
and CD44 knockdown BCSCs were similar. These
results suggest that CD44 knockdown decreased prolif-
erating ability and extended S phase to increase the
similarities with non-BCSCs.
Tumorigenesis of CD44 knockdown BCSCs compared with
BCSCs and non-BCSCs in NOD/SCID mice
The tumor-causing potential of the cells was evaluated
to assess the differentiated phenotype after CD44 knock-
down. BCSCs caused tumors in 66.67% (2/3) of mice
with 10
3 cells, while 10
6 non-BCSCs were needed to
cause tumors in 25% of mice (1/3). The tumor-causing
potential was reduced in the CD44 knockdown BCSCs,
with doses of 10
4 cells causing tumors in 0% of mice,
compared with 100% of mice before CD44 down-regula-
tion (Figure 7). At doses of 10
5 grafted cells, BCSCs
were capable of generating tumors in up to 100% of
mice (3/3), compared with only 33.33% (1/3) of mice in
t h ec a s eo fC D 4 4k n o c k d o w nB C S C s .F i g u r e7 As h o w s
that injection with 10
6 BCSCs caused large tumors (on
the right), while 10
6 CD44 knockdown BCSCs failed to
produce any tumors (on the left). This suggests that
knockdown of CD44 caused differentiation and loss of
the stemness characteristics of BCSCs.
Discussion
The effectiveness of breast cancer treatment currently
remains low. This may be attributable to the existence
of a small population of cancer stem cells with high
resistance to chemotherapy and radiation therapy, which
can thus be responsible for high rates of relapse after
treatment, as well as for metastasis. Cancer stem-cell-
targeting therapy thus represents a promising potential
therapy for the treatment of breast cancer. In this study,
we evaluated the role of CD44 in maintaining stemness
Figure 5 Expression levels of genes related to metastasis (A), cell viability, proliferation and anti-tumor drug resistance (B) in BCSCs,
non-BCSCs and CD44 knockdown BCSCs normalized to GAPDH. Knockdown: CD44 knockdown BCSCs.
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Page 8 of 13and inhibiting the differentiation of BCSCs. Previous
studies suggested that downregulation of CD44 allowed
BCSCs to differentiate into cancer non-BCSCs or nor-
mal cells in breast tissue. To confirm this, we initially
isolated BCSCs from malignant breast tumors based on
their CD44 and CD24 expression pattern.
To determine the contribution of CD44 to the charac-
teristics of BCSCs, we performed CD44 knockdown
using a shRNA lentiviral vector and puromycin selec-
tion. This method was more effective than siRNA for
generating a stable and pure cell population lacking
CD44 expression, which could then be compared with
non-knockdown cells.
The stemness of the CD44 knockdown cells was eval-
uated based on three criteria: the expression of genes
related to stem cells, metastasis, and drug resistance;
changes in the cell cycle; and the ability to form tumors
in vivo in a NOD/SCID mouse model.
CD44 knockdown cells showed dramatically changed
gene expression patterns compared with the original
cells. Genes associated with the metastatic ability of
cancer stem cells, especially Muc-1, MMP9 and Myc,
were strongly reduced by CD44 knockdown. Mucin 1 is
encoded by the Muc-1 gene. Mucin-1 protects the body
from infection by binding pathogens to oligosaccharides
via the extracellular domain, thus preventing the patho-
gen from reaching the cell surface [25,26]. Mucin-1 also
functions in a cell-signaling capacity [27]. Over-expres-
sion of Muc-1 is often associated with colon, breast,
ovarian, lung and pancreatic cancers [28]. Mucin-1
plays important roles in cancer development and metas-
tasis by inhibiting the anti-tumor immune response
[29], promoting the growth of cancer cells by binding
to EGFR in an epidermal growth factor-dependent man-
ner [30], preventing cell death by inhibition of p53-
mediated apoptosis and promotion of p53-mediated cell
cycle arrest [31], and promoting cancer metastasis
[32-34]. Because Mucin-1 promotes the expression of
Myc [35], levels of Myc expression were also decreased
in association with Mucin-1 down-regulation, with con-
sequent effects on the metastatic ability of BCSCs. A
recent study by Fessler et al. showed that Mucin-1 was
a determinant of trastuzumab (Herceptin) resistance in
breast cancer cells, as well as being associated with
resistance to taxol, doxorubicin, and cyclophosphamide
[36]. Low expression of Mucin-1 would thus be
expected to decrease metastasis and drug resistance in
BCSCs.
Figure 6 Similar cell cycles in non-BCSCs (B, E, H), and CD44 knockdown BCSCs (C, F, I) cells compared with BCSCs (A, D, G).G 1 / G 0
phase was relatively unchanged, but G2/M phase decreased and S phase increased in CD44 knockdown BCSCs.
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CD44 knockdown cells. EGFR is often strongly
expressed in many cancers [37,38], including breast can-
cer. However, BCSCs that weakly express this gene are
unaffected by drugs that attack the EGFR, such as gefiti-
nib, erlotinib, and cetuximab. The reduction of CD44
expression increased EGFR expression to a level similar
to that in non-BCSCs, which are sensitive to chemother-
apy. Cyclin D1 is encoded by the G1/S-specific CCND1
gene, and increased expression of cyclin D1 thus caused
cells to move rapidly into S phase. However, cyclin E2
expression was not increased by CD44 knockdown, and
cells were therefore mainly stopped in phase G1/S. The
results of cell cycle analysis were in accord with these
explanations.
Gene expression analysis also showed down-regulation
of Bcl-2 by CD44 knockdown. Bcl-2 is capable of inhi-
biting anticancer drug-induced apoptosis mediated by
the voltage-dependent anion channel in the outer mito-
chondrial membrane, and over-expression of Bcl-2 and
Bcl-XL might confer resistance to chemotherapy [39].
Cells with low Bcl-2 gene expression are more sensitive
to chemotherapy. Previous studies showed that CD44
knockdown cells were more sensitive to doxorubicin
than BCSCs, similar to breast cancer cells [24]. FASN
was also down-regulated inC D 4 4k n o c k d o w nB C S C s .
FASN expression is up-regulated in the early steps of
breast cancer and represents a therapeutic target for
breast cancer metastasis [40,41] and liposarcoma [42].
Inhibition of FASN suppressed the growth of cancer
stem-like cells in breast cancer [43] and colon cancer
[44], and induced apoptosis in diffuse large B-cell lym-
phoma [45] and in gastric-tumor-bearing mice [46].
CD44 knockdown was also associated with down-regula-
tion of heat shock transcription factor 1 (HSF1) to a
level similar to that seen in non-BCSCs. HSF1 is a
major transactivator of genes coding for heat shock pro-
teins. HSF1 is involved in tumor initiation, maintenance,
and progression by regulating the expression of heat
shock proteins [47]. Down-regulation of HSF1 decreased
cell proliferation and enhanced sensitivity to hyperther-
mia in human melanoma cell lines [48]. It has thus been
considered as a promising target for anti-cancer treat-
ment [49], especially in breast cancer [50].
LEF1 up-regulates Oct4 promoter activity and physi-
cally interacts with Nanog; these comprise two key com-
ponents of embryonic stem cell pluripotency. Down-
regulation of LEF1 by siRNA induced differentiation of
mouse embryonic stem cells [33]. The low expression of
LEF1 in non-BCSCs and the down-regulation of LEF1
by CD44 knockdown indicated the differentiation of
BCSCs into non-BCSCs. Moreover, LEF1, TCF7 and
Myc are all members of the Wnt signaling pathway, and
their down-regulation thus represents suppression of the
Wnt signaling pathway. Similarly Bcl-2, MMP7,a n d
Myc are members of the PI3K/AKT pathway; HSF1,
TP53,a n dMyc belong to the Stress signaling pathway;
and PTCH1, PKRCE, PTGS2 (Cox-2),a n dIL4R are
members of the Hedgehog, calcium and protein kinase
C, and Jak-Stat pathways, respectively. Their reduced
expression following CD44 knockdown demonstrated its
effect on several signaling pathways. The Wnt, Hedge-
hog and Jak-Stat pathways are important pathways in
stem cells and cancer stem cells and have been consid-
ered as promising therapeutic targets [51-54]. Down-
regulation of some key signaling pathway genes proved
that CD44 knockdown BCSCs underwent phenotypic
changes from cancer stem cells to cancer cells or nor-
mal cells. Down-regulation of the Stress and calcium
protein kinase C pathways might increase the sensitivity
of CD44 knockdown BCSCs to some anti-tumor drugs,
such as doxorubicin, because the Stress and protein
kinase C pathways help cancer cells to cope with stress
and changes of environment.
Figure 7 Tumorigenic capacities of CD44 knockdown BCSCs,
BCSCs and non-BCSCs in NOD/SCID mice. CD44 knockdown
BCSCs and non-BCSCs were similar, but there was a significant
difference in tumorigenic capacity between CD44 knockdown
BCSCs and BCSCs (B). Injection of 10
6 BCSCs caused large tumors
(right), while 10
6 CD44 knockdown BCSCs failed to produce any
tumors (left) (A).
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knockdown BCSCs drove the cell cycle towards that
seen in non-BCSCs. S-phase cells were increased and
G2/M cells decreased in CD44 knockdown BCSCs and
non-BCSCs compared with BCSCs. These cell cycle
results resembled those found in cancer stem cells from
solid tumors isolated on the basis of CD133 expression,
showing that cancer stem cells were mainly in G2/M
phase [55]. Karimi-Busheri et al. compared the cell
cycles of mammosphere-forming and adhesive cells in
cancer stem cells isolated from MCF-7 cell lines; most
adhesive cells were in S phase, while mammosphere-
forming cells were concentrated in the G2/M phase
[56]. Thus, CD44 knockdown appeared to drive BCSCs
toward a non-BCSC phenotype and differentiation.
The main physiological difference between cancer
stem cells and the remaining cells in the tumor is their
different tumorigenic potentials when transplanted into
mice. Tumorigenic potential thus represents the gold
standard for demonstrating a change in stemness of
BCSCs. The tumorigenic potential of CD44 knockdown
BCSCs in this study was reduced to that of non-BCSCs.
Many previous studies found that as few as 50-100
BCSCs were adequate to generate tumors in NOD/SCID
mice [3], while others found that 10
3 cancer stem cells
could cause tumors [4,57]. In the current study, grafts
of 10
3 BCSCs were capable of producing tumors in
SCID mice, whereas CD44 knockdown BCSCs required
at least 10
6 cells, similar to the situation for non-BCSCs.
The altered biological characteristics of these cells indi-
cated that CD44 knockdown changed the stem cell phe-
notype with high tumor-causing potential into cells with
lower tumor-causing potential, representing differentia-
tion of the cancer stem cells.
Differentiation therapy targeting cancer stem cells is
currently under investigation by many groups, particu-
larly focusing on the use of chemicals to cause stem
cell differentiation. Takehara et al. showed that BCSCs
differentiated when treated with acetaminophen, which
also inhibited tumor formation in a nude mouse model
[58]. Estrogen also causes BCSCs to differentiate, as
demonstrated by a reduction in the number of cancer
stem cells in tumors positive for estrogen receptors
[59]. All-trans retinoic acid (ATRA) can prevent breast
cancer recurrence by inducing BCSC differentiation
and cell cycle arrest [2,60]. BCSCs may also be affected
in terms of stem cell self-renewal, differentiation, moti-
lity and mesenchymal phenotype after treatment with
the polyamine analog [1 N, 12 N] bis (ethyl)-cis -6.7-
dehydrospermine (PG11047) [61]. Similarly, Roy et al.
found that ATRA, trichostatin A and vorinostat caused
dose-dependent decreases in the BCSC population, and
showed that these differentiating agents reduced the
number of BCSCs within the MCF7 cell line.
Mammosphere formation in primary breast cancers
(n = 3) was decreased by ≥ 25% by ATRA treatment
combined with 6 Gy irradiation, compared with irra-
diation alone [62].
T h er e s u l t so ft h ec u r r e n ts t u d ys h o w e dt h a tC D 4 4
plays an important role in the maintenance of BCSC
stemness. Because inhibition of CD44 expression caused
differentiation of BCSCs as well as reduced anti-tumor
drug resistance [24], it is possible that gene therapy
designed to interfere with CD44, as well as other factors
that could reduce CD44 expression, represent promising
therapeutic strategies for treating breast cancer, espe-
cially in combination with radiation or other anti-tumor
agents.
This study used CD44 shRNA lentiviral particles to
generate a stable CD44 knockdown BCSC population,
with clear modifications in gene expression and cell
characteristics. However, reverse-transcribed DNA can
randomly insert into the cell genome and potentially
disturb the function of cellular genes, leading to the
activation of oncogenes and thus promoting the devel-
opment of cancer. However, previous studies found that
lentiviral vectors had a low tendency to integrate in
places that caused cancer [63], and one study found no
increase in tumor incidence and no earlier onset of
tumors in a mouse strain following the use of lentiviral
vectors [64]. In addition, we randomly evaluated 10
colonies and found similar results in terms of gene
expression. Given that lentivirus integration is random,
the 10 colonies would be exceptionally unlikely to con-
tain similar insertion sites to disrupt the function of the
genes.
Conclusions
Down-regulation of CD44 caused changes in the pheno-
type of BCSCs. CD44 knockdown BCSCs lost the BCSC
phenotype and showed reduced expression of genes
related to stemness, metastasis and tumorigenesis, espe-
cially Muc-1 and Bcl-2. In addition, the cell cycle chan-
ged to resemble that seen in differentiated cells (non-
BCSCs), and anti-tumor drug resistance and tumori-
genic potential in NOD/SCID mice were both reduced.
These data indicate that BCSCs were differentiated into
non-BCSCs by CD44 knockdown. These results suggest
that a combination of differentiation therapy aimed at
down-regulation of CD44 in BCSCs, together with che-
mical or radiation therapies, represents a promising
therapeutic strategy for the treatment of breast cancer,
and also suggest that RNAi gene therapy could provide
a novel differentiation strategy.
Acknowledgements
This work was funded by grants from the Vietnam National Project about
Breast Cancer, Ministry of Science and Technology, Vietnam (Code:
Pham et al. Journal of Translational Medicine 2011, 9:209
http://www.translational-medicine.com/content/9/1/209
Page 11 of 13DTDL.2011-T/30). We thank the Oncology Hospital at Ho Chi Minh for
supplying the malignant breast cancer tumors.
Author details
1Laboratory of Stem Cell Research and Application, University of Science,
Vietnam National University, 227 Nguyen Van Cu, District 5, HCM City,
Vietnam.
2Department of Immunology, Vietnam Military Medical University,
104 Phung Hung, Ha Dong, Ha Noi, Vietnam.
Authors’ contributions
All authors read and approved the final manuscript. PVP carried out studies
including primary culture, isolation of breast cancer stem cells, gene
expression analysis and designed the study and drafted the manuscript in
cooperation with all other authors. NLCP and NTN performed the
knockdown of CD44 by shRNA. NHT and TTD participated in the in vivo
animal experiments. DVL and KDT participated in the cell cycle and flow
cytometry analysis. NKP participated in designing the study and drafted the
manuscript in cooperation with all other authors, and also checked PCR
primers.
Competing interests
The authors declare that they have no competing interests.
Received: 2 September 2011 Accepted: 7 December 2011
Published: 7 December 2011
References
1. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF:
Prospective identification of tumorigenic breast cancer cells. Proc Natl
Acad Sci USA 2003, 100(7):3983-8.
2. Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F, Wicha MS,
Birnbaum D, Charafe-Jauffret E: Retinoid signaling regulates breast cancer
stem cell differentiation. Cell Cycle 2009, 8(20):3297-302.
3. Wright MH, Calcagno AM, Salcido CD, Carlson MD, Ambudkar SV,
Varticovski L: Brca1 breast tumors contain distinct CD44+/CD24- and
CD133+ cells with cancer stem cell characteristics. Breast Cancer Res 2008,
10(1):R10.
4. Phuc PV, Khuong TTT, Dong LV, Kiet TD, Giang TT, Ngoc PK: Isolation and
characterization of breast cancer stem cells from malignant tumours in
Vietnamese women. JCAB 2010, 4(12):163-16.
5. Dave B, Chang J: Treatment resistance in stem cells and breast cancer. J
Mammary Gland Biol Neoplasia 2009, 14:79-82.
6. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA, Rosen JM:
WNT/beta-catenin mediates radiation resistance of mouse mammary
progenitor cells. Proc Natl Acad Sci USA 2007, 104(2):618-23.
7. Wang S, Yang D, Lippman ME: Targeting Bcl-2 and Bcl-XL with
nonpeptidic small-molecule antagonists. Semin Oncol 2003, 30(5 Suppl
16):133-42.
8. Frosina G: DNA repair and resistance of gliomas to chemotherapy and
radiotherapy. Mol Cancer Res 2009, 7(7):989-99.
9. Asselin-Labat ML, Shackleton M, Stingl J, Vaillant F, Forrest NC, Eaves CJ,
Visvader JE, Lindeman GJ: Steroid hormone receptor status of mouse
mammary stem cells. J Natl Cancer Inst 2006, 98(14):1011-4.
10. Horwitz KB, Dye WW, Harrell JC, Kabos P, Sartorius CA: Rare steroid
receptor-negative basal-like tumorigenic cells in luminal subtype human
breast cancer xeno-grafts. Proc Natl Acad SciUSA 2008, 147(9):4056-66.
11. Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A,
Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, Fan C, Zhang X, He X,
Pavlick A, Gutierrez MC, Renshaw L, Larionov AA, Faratian D, Hilsenbeck SG,
Perou CM, Lewis MT, Rosen JM, Chang JC: Residual breast cancers after
conventional therapy display mesenchymal as well as tumor-initiating
features. Proc Natl Acad SciUSA 2009, 106(33):13820-5.
12. Vorechovsky’ I, Benediktsson KP, Toftgård R: The patched/hedgehog/
smoothened signalling pathway in human breast cancer: No evidence
for H133Y SHH, PTCH and SMO mutations. Eur J Cancer 1999, 35(5):711-3.
13. Soriano JV, Uyttendaele H, Kitajewski J, Montesano R: Expression of an
activated Notch4(int-3) oncoprotein disrupts morphogenesis and
induces an invasive phenotype in mammary epithelial cells in vitro. Int J
Cancer 2000, 86:652-659.
14. Huelsken J, Vogel R, Brinkmann V, Erdmann B, Birchmeier C, Birchmeier W:
Requirement for beta-catenin in anterior-posterior axis formation in
mice. J Cell Biol 2000, 148(3):567-78.
15. Kelly OG, Pinson KI, Skarnes WC: The Wnt co-receptors Lrp5 and Lrp6 are
essential for gastrulation in mice. Development 2004, 131(12):2803-15.
16. Pasca di Magliano M, Hebrok M: Hedgehog signalling in cancer formation
and maintenance. Nat Rev Cancer 2003, 3(12):903-11.
17. Karhadkar SS, Bova GS, Abdallah N, Dhara S, Gardner D, Maitra A, Isaacs JT,
Berman DM, Beachy PA: Hedgehog signalling in prostate regeneration,
neoplasia and metastasis. Nature 2004, 431(7009):707-12.
18. Liu S, Dontu G, Wicha MS: Mammary stem cells, self-renewal pathways,
and carcinogenesis. Breast Cancer Res 2005, 7(3):86-95.
19. Korkaya H, Paulson A, Iovino F, Wicha MS: HER2 regulates the mammary
stem/progenitor cell population driving tumorigenesis and invasion.
Oncogene 2008, 27(47):6120-30.
20. Mariani G, Fasolo A, De Benedictis E, Gianni L: Trastuzumab as adjuvant
systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol
2009, 6(2):93-104.
21. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P,
Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D: PTEN activation
contributes to tumor inhibition by trastuzumab, and loss of PTEN
predicts trastuzumab resistance in patients. Cancer Cell 2004, 6(2):117-27.
22. Carlsson J, Nordgren H, Sjöström J, Wester K, Villman K, Bengtsson NO,
Ostenstad B, Lundqvist H, Blomqvist C: HER2 expression in breast cancer
primary tumours and corresponding metastases. Original data and
literature review. Br J Cancer 2004, 90(12):2344-8.
23. Adamia S, Maxwell CA, Pilarski LM: Hyaluronan and hyaluronan synthases:
potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc
Haematol Disord 2005, 5(1):3-14.
24. Phuc PV, Nhan PLC, Nhung TH, Tam NT, Hoang NM, Tue VG, Thuy DT,
Ngoc PK: Downregulation of CD44 reduces doxorubicin resistance of
CD44
+CD24
- breast cancer cells. Onco Targets Ther 2011, 4:71-8.
25. Singh PK, Hollingsworth MA: Cell surface-associated mucins in signal
transduction. Trends Cell Biol 2006, 16(9):467-476.
26. Moncada DM, Kammanadiminiti SJ, Chadee K: Mucin and Toll-like
receptors in host defense against intestinal parasites. Trends Parasitol
2003, 19(7):305-311.
27. Linden SK, Sheng YH, Every AL, Miles KM, Skoog EC, Florin TH, Sutton P,
McGuckin MA, Van Nhieu , Guy Tran : MUC1 limits Helicobacter pylori
infection both by steric hindrance and by acting as a releasable decoy.
PLoS Pathog 2009, 5(10):e1000617.
28. Gendler SJ: MUC1, the renaissance molecule. J Mammary Gland Biol
Neoplasia 2001, 6(3):339-353.
29. Hollingsworth MA, Swanson BJ: Mucins in cancer: protection and control
of the cell surface. Nat Rev Cancer 2004, 4(1):45-60.
30. Pochampalli MR, el Bejjani RM, Schroeder JA: MUC1 is a novel regulator of
ErbB1 receptor trafficking. Oncogene 2007, 26(12):1693-1701.
31. Wei X, Xu H, Kufe D: Human MUC1 oncoprotein regulates p53-responsive
gene transcription in the genotoxic stress response. Cancel Cell 2005,
7(2):167-178.
32. Yamamoto M, Bharti A, Li Y, Kufe D: Interaction of the DF3/MUC1 breast
carcinoma-associated antigen and beta-catenin in cell adhesion. J Biol
Chem 1997, 272(19):12492-4.
33. Huang C, Qin D: Role of Lef1 in sustaining self-renewal in mouse
embryonic stem cells. J Genet Genomics 2010, 37(7):441-9.
34. Roy LD, Sahraei M, Subramani DB, Besmer D, Nath S, Tinder TL, Bajaj E,
Shanmugam K, Lee YY, Hwang SIL, Gendler SJ, Mukherjee P: MUC1
enhances invasiveness of pancreatic cancer cells by inducing epithelial
to mesenchymal transition. Oncogene 2011, 30(12):1449-59.
35. Ren J, Raina D, Chen W, Li G, Huang L, Kufe D: MUC1 oncoprotein
functions in activation of fibroblast growth factor receptor signaling. Mol
Cancer Res 2006, 4(11):873-883.
36. Fessler SP, Wotkowicz MT, Mahanta SK, Bamdad C: MUC1 is a determinant
of trastuzumab (Herceptin) resistance in breast cancer cells. Breast Cancer
Res Treat 2009, 118(1):113-24.
37. Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R, Greene MI: ErbB
receptors: from oncogenes to targeted cancer therapies. J Clin Invest
2007, 117(8):2051-8.
38. Walker F, Abramowitz L, Benabderrahmane D, Duval X, Descatoire VR,
Hénin D, Lehy TRS, Aparicio T: Growth factor receptor expression in anal
squamous lesions: modifications associated with oncogenic human
Pham et al. Journal of Translational Medicine 2011, 9:209
http://www.translational-medicine.com/content/9/1/209
Page 12 of 13papillomavirus and human immunodeficiency virus. Human Pathology
2009, 40(11):1517-27.
39. Verrier F, Deniaud A, Lebras M, Metivier D, Kroemer G, Mignotte B, Jan G,
Brenner C: Dynamic evolution of the adenine nucleotide translocase
interactome during chemotherapy-induced apoptosis. Oncogene 2004,
23:8049-8064.
40. Lupu R, Menendez JA: Targeting fatty acid synthase in breast and
endometrial cancer: An alternative to selective estrogen receptor
modulators? Endocrinology 2006, 147(9):4056-66.
41. Gonzalez-Guerrico A, Lupu R: Fatty Acid Synthase (FASN) as a Therapeutic
Target for Breast Cancer Metastasis. Cancer Res 2009, 69(24 Suppl),
Abstract nr 6160.
42. Olsen AM, Eisenberg BL, Kuemmerle NB, Flanagan AJ, Morganelli PM,
Lombardo PS, Swinnen JV, Kinlaw WB: Fatty acid synthesis is a
therapeutic target in human liposarcoma. Int J Oncol 2010, 36(5):1309-14.
43. Pandey PR, Okuda H, Watabe M, Pai SK, Liu W, Kobayashi A, Xing F,
Fukuda K, Hirota S, Sugai T, Wakabayashi G, Koeda K, Kashiwaba M,
Suzuki K, Chiba T, Endo M, Fujioka T, Tanji S, Mo YY, Cao D, Wilber AC,
Watabe K: Resveratrol suppresses growth of cancer stem-like cells by
inhibiting fatty acid synthase. Breast Cancer Res Treat 2010.
44. Murata S, Yanagisawa K, Fukunaga K, Oda T, Kobayashi A, Sasaki R,
Ohkohchi N: Fatty acid synthase inhibitor cerulenin suppresses liver
metastasis of colon cancer in mice. Cancer Sci 2010, 101(8):1861-5.
45. Uddin S, Hussain AR, Ahmed M, Bu R, Ahmed SO, Ajarim D, Al-Dayel F,
Bavi P, Al-Kuraya KS: Inhibition of fatty acid synthase suppresses c-Met
receptor kinase and induces apoptosis in diffuse large B-cell lymphoma.
Mol Cancer Ther 2010, 9(5):1244-55.
46. Dowling S, Cox J, Cenedella RJ: Inhibition of fatty acid synthase by
Orlistat accelerates gastric tumor cell apoptosis in culture and increases
survival rates in gastric tumor bearing mice in vivo. Lipids 2009,
44(6):489-98.
47. Meng L, Gabai VL, Sherman MY: Heat-shock transcription factor HSF1 has
a critical role in human epidermal growth factor receptor-2-induced
cellular transformation and tumorigenesis. Oncogene 2010,
29(37):5204-13.
48. Nakamura Y, Fujimoto M, Hayashida N, Takii R, Nakai A, Muto M: Silencing
HSF1 by short hairpin RNA decreases cell proliferation and enhances
sensitivity to hyperthermia in human melanoma cell lines. J Dermatol Sci
2010, 60(3):187-92.
49. Whitesell L, Lindquist S: Inhibiting the transcription factor HSF1 as an
anticancer strategy. Expert Opin Ther Targets 2009, 13(4):469-78.
50. Calderwood SK: Heat shock proteins in breast cancer progression–a
suitable case for treatment? Int J Hyperthermia 2010, 26(7):681-5.
51. Takebe Naoko, Harris JPamela, Warren QRonald, Percy Ivy S: Targeting
cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways.
Nature Reviews Clinical Oncology 2011, 8(2):97-106.
52. Suling Liu, Wicha SMax: Targeting Breast Cancer Stem Cells. JCO 2010,
28(25):4006-4012.
53. Curtin JC, Lorenzi MV: Drug discovery approaches to target Wnt signaling
in cancer stem cells. Oncotarget 2010, 1(7):563-77.
54. Hernandez-Vargas H, Ouzounova M, Le Calvez-Kelm F, Lambert MP, McKay-
Chopin S, Tavtigian SV, Puisieux A, Matar C, Herceg Z: Methylome analysis
reveals Jak-STAT pathway deregulation in putative breast cancer stem
cells. Epigenetics 2010, 6(4):428-39.
55. Tirino V, Desiderio V, d’Aquino R, De Francesco F, Pirozzi G, Graziano A,
Galderisi U, Cavaliere C, De Rosa A, Papaccio G, Giordano A: Detection and
characterization of CD133+ cancer stem cells in human solid tumours.
PLoS One 2008, 3(10):e3469.
56. Karimi-Busheri F, Rasouli-Nia A, Mackey JR, Weinfeld M: Senescence evasion
by MCF-7 human breast tumor-initiating cells. Breast Cancer Res 2010,
12(3):R31.
57. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S,
Pierotti MA, Daidone MG: Isolation and in vitro propagation of
tumorigenic breast cancer cells with stem/progenitor cell properties.
Cancer Res 2005, 65(13):5506-11.
58. Takehara M, Hoshino T, Namba T, Yamakawa N, Mizushima T:
Acetaminophen-induced differentiation of human breast cancer stem
cells and inhibition of tumor xenograft growth in mice. Biochem
Pharmacol 2011, 81(9):1124-35.
59. Simões BM, Vivanco MD: Cancer stem cells in the human mammary
gland and regulation of their differentiation by estrogen. Future Oncol
2011, 7(8):995-1006.
60. Li RJ, Ying X, Zhang Y, Ju RJ, Wang XX, Yao HJ, Men Y, Tian W, Yu Y,
Zhang L, Huang RJ, Lu WL: All-trans retinoic acid stealth liposomes
prevent the relapse of breast cancer arising from the cancer stem cells.
J Control Release 2011, 149(3):281-91.
61. Cirenajwis H, Smiljanic S, Honeth G, Hegardt C, Marton LJ, Oredsson SM:
Reduction of the putative CD44+CD24- breast cancer stem cell
population by targeting the polyamine metabolic pathway with
PG11047. Anticancer Drugs 2010, 21(10):897-906.
62. Roy R, Willan P, Clarke R, Farnie G: Differentiation therapy: targeting
breast cancer stem cells to reduce resistance to radiotherapy and
chemotherapy. Breast Cancer Res 2010, 12(Suppl 1):O5.
63. Cattoglio C, Facchini G, Sartori D, Antonelli A, Miccio A, Cassani B,
Schmidt M, von Kalle C, Howe S, Thrasher AJ, Aiuti A, Ferrari G, Recchia A,
Mavilio F: Hot spots of retroviral integration in human CD34+
hematopoietic cells. Blood 2007, 110(6):1770-8.
64. Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C,
Sergi Sergi L, Benedicenti F, Ambrosi A, Di Serio C, Doglioni C, von Kalle C,
Naldini L: Hematopoietic stem cell gene transfer in a tumor-prone
mouse model uncovers low genotoxicity of lentiviral vector integration.
Nat Biotechnol 2006, 24(6):687-696.
doi:10.1186/1479-5876-9-209
Cite this article as: Pham et al.: Differentiation of breast cancer stem
cells by knockdown of CD44: promising differentiation therapy. Journal
of Translational Medicine 2011 9:209.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pham et al. Journal of Translational Medicine 2011, 9:209
http://www.translational-medicine.com/content/9/1/209
Page 13 of 13